BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20630825)

  • 1. Src inhibitors in lung cancer: current status and future directions.
    Rothschild SI; Gautschi O; Haura EB; Johnson FM
    Clin Lung Cancer; 2010 Jul; 11(4):238-42. PubMed ID: 20630825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
    Mayer EL; Krop IE
    Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
    Saad F; Lipton A
    Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src kinase inhibitors: promising cancer therapeutics?
    Creedon H; Brunton VG
    Crit Rev Oncog; 2012; 17(2):145-59. PubMed ID: 22471705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
    Herbst RS; Oh Y; Wagle A; Lahn M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Src continues aging: current and future clinical directions.
    Kopetz S; Shah AN; Gallick GE
    Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
    Krystal GW; DeBerry CS; Linnekin D; Litz J
    Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SRC inhibitors.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S466-7. PubMed ID: 21102241
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G; Schafhausen P; Brummendorf TH
    Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
    Klener P; Klener P
    Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
    Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
    Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRC: a century of science brought to the clinic.
    Aleshin A; Finn RS
    Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
    Lee D; Gautschi O
    Clin Lung Cancer; 2006 May; 7(6):381-4. PubMed ID: 16800962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src signaling in cancer invasion.
    Guarino M
    J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA
    Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Src inhibitors in breast cancer therapy.
    Hiscox S; Nicholson RI
    Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.